CC BY
10
Abstracts. PHYTOPHARM 2017
FREQUENCY AND SIZE OF HEPATOCARCINOMAS DECREASE IN CBA INBRED MICE UNDER PREVENTIVE ADMINISTRATION OF MULTIPHYTOADAPTOGENE COMPLEX DRY POWDER
© BocharovE.V.1, Bocharova O.A.1, Karpova R.V.1, Vershinskaya A.A.1, Kucheryanu V.G.2
1 N.N. Blokhin Cancer Research Center, Moscow, Russia;
2 The institute of general pathology and pathophysiology, Moscow, Russia
The aim of this investigation was to evaluate the frequency and size of hepatocarcinomas in CBA inbred mice using multyphytoadaptogene complex dry powder (DMPAC) in early ontogenesis. DMPAC was produced by a special desiccation technology of forty medical herbs water-ethanol extracts mixture (MPAC). MPAC has a wide spectrum of activities including immunomodifying effects [1, 3]. The study was carried out on 131 mice-males of CBA inbred strain. This mice strain is a classical model of cancer susceptibility exhibiting high risk for spontaneous hepatomas [2]. The animals were administered 0,3% DMPAC water solution during the first month of life including the final time period of liver differentiation (as preventive application). Tumour volumes (mm3) were evaluated according to the standard formula. Hepatomas were visible in 15% of control mice at the age of 8 months. Tumours' number per mouse was 0,20 ± 0,10, the average volume of one tumour was 22,6 ± 11,9 mm3, the total hepatomas mass per one animal was 4,5 ± 3,1 mm3. No tumours were seen in the "preventive" group. Hepatomas were found in all control animals (100%) at the age of 22 months. Tumours' number per mouse was 2,8 ± 0,5, the average volume of one tumour was 393,6 ± 102,3 mm3, the total hepatomas mass per one animal was
1120,2 ± 350,5 mm3. At the same time in the DMPAC-exposed mice the tumours occurred with lower frequency (in 66,7% of mice, p < 0,001). The hepatomas number per mouse (1,5 ± 0,4; p = 0,03) and total hepatomas mass per one animal (378,9 ± 126,8; p = 0,04 mm3) were lower than in the control group. However the average volume of one tumor (258,4 ± 71,3 mm3) did not differ statistically from control mice (p = 0,35). Thus, preventive administration of DMPAC during the 1 month of postnatal ontogenesis promotes the reduction of tumours' frequency (for 33,3%), the number per mouse and total hepatomas mass per animal. These results demonstrate a preventive effect for DMPAC able to down-regulate hepatocarcinomas formation in mice-males of CBA inbred strain.
References:
1. Bocharov EV, Kucheryanu VG, Kryzhanovsky GN, Belorustseva SA, Bocharova OA, Kudrin VS, 2006. Bull of Exper Biol and Med. 141(5):560-563.
2. Bocharova OA, Modianova EA, 1982. Ontogenez., 13(4):427-429.
3. Chulkova SV, Bocharova OA, Klimenkov AA, Karpova RV, Benevskyi AI, Gorozhanskaya EG, 2006. Russ. J. of Biotherapy, 5(2):85-92.
SAFETY ISSUES OF INTERACTIONS BETWEEN TRADITIONAL MEDICINES AND PHARMACEUTICAL MEDICINES
© Kelvin Chan
School of Pharmacy Biomolecular Sciences, Liverpool John Moores University, UK, and The NICM, Western Sydney University, Australia
The increasing popularity world-wide of using herbal medicinal materials (HMM) from ethnic traditional medicine such as the widely used Chinese materia medica (CMM) or other ethnic herbal medicines and related proprietary health products (PHP), functional food and prescription herbal medicines has raised concerns over their concomitant use with pharmaceutical medicines (PHARMED) and the consequential adverse effects [1]. In most cases the alleged causes of adverse effects are linked with herbal substances, although the authoritive information on the interactions between HMM/PHP and PHARMED is not plentiful in the literature. In the 21st century, the public are more informed, from the internet, about health and medical products and become more knowledgeable about matters relating to their health
conditions and well-being in curing and preventing illnesses. They often self-medicate themselves with various health products as well as those over-the-counter (OTC) PHARMED. Some of these products may have doubtful quality control and contain harmful additives or unchecked ingredients (2). The future professionals in health and medical care should be knowledgeable or aware of what their patients have been taking or given. Their combining medications may be involved with possible outcomes of adverse reactions or beneficial effects. In actual practice the patients may receive both treatments intentionally or unintentionally, with or without the awareness of the practitioner. In these situations an available authoritive database for interactions between HMM/PHP or prescribed PHARMED will be extremely
Obzory po kliniceskoj farmacologii i lekarstvennoj terapii [Reviews of clinical pharmacology and drug therapy] vol. 15/2017/suppLement 1
1 15
